東陽光(600673.SH):控股子公司參與全國藥品集中採購擬中選
格隆匯2月3日丨東陽光(600673.SH)公佈,2021年2月3日,公司控股子公司宜昌東陽光長江藥業股份有限公司(以下簡稱“東陽光藥”)與東莞市陽之康醫藥有限責任公司(以下簡稱“陽之康醫藥”)參加了聯合採購辦公室(以下簡稱“聯採辦”)組織的第四批全國藥品集中採購的投標工作。
根據聯採辦發佈的全國藥品集中採購擬中選結果公示,公司產品鹽酸度洛西汀腸溶膠囊、左氧氟沙星片、替米沙坦片、艾司奧美拉唑鎂腸溶膠囊擬中選本次集中採購,並且公司根據各省市場潛力進行了省份遴選,中選結果公示3天后正式發佈。
本次擬中選產品中替米沙坦片2019年度銷售收入為5245.91萬元,約佔公司2019年度營業收入總額的0.0036%,2020年三季度銷售收入為2190.66萬元,約佔公司2020年三季度營業收入總額的0.0027%;左氧氟沙星片2020年三季度銷售收入為927.74萬元,約佔公司2020年三季度營業收入總額的0.0011%;鹽酸度洛西汀腸溶膠囊及艾司奧美拉唑鎂腸溶膠囊分別於2021年、2020年取得《藥品註冊證書》,目前尚無銷售數據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.